Clinical Trial Update: BL22 Immunotoxin In Treating Young Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Non-Hodgkin's Lymphoma [Phase 1]

View source ↗

Summary

The update indicates that the Phase 1 trial of the BL22 immunotoxin for relapsed or refractory acute lymphoblastic leukemia or non-Hodgkin lymphoma in young pat…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• Non-hodgkin Lymphoma

Drugs mentioned

• BL22 Immunotoxin (BL22 immunotoxin)

Snippet

Sponsor: MedImmune LLC | Conditions: Leukemia, Lymphoma | Phase 1 | Status: SUSPENDED